In a world where economic growth increasingly depends on “intangible” products and services based on human know-how, knowledge and creativity, only those countries that have the right policy attitude to innovation will thrive.
Trade and Intellectual Property
January 31, 2019
Canadian courts, in particular the Supreme Court of Canada, have in recent years issued intellectual property (IP) judgments that were problematic, even erroneous, Munk Senior Fellow Richard Owens said today.
December 14, 2017
The long-awaited Draft Intellectual Property (IP) Policy, recently published by the Department of Trade and Industry (dti), proposes several key reforms to South Africa’s IP policy.
August 3, 2017
The Macdonald-Laurier Institute has released a series of three papers, in the Defending our Rights series, which details how Canada can become a global intellectual property leader.
July 8, 2017
The MacDonald-Laurier Institute's Richard Owens writes that a ruling in Access Copyright v. York University issued by Judge Phelan of the Federal Court of Canada represented a significant victory for Canadian content creators.
July 7, 2017
The Macdonald-Laurier Institute's Richard Owens writes that Canada's effective decision to reverse the so-called promise doctrine, a more expansive test of patent utility, is an important step forward for Canadian patent law.
May 31, 2017
This report is the first in a series of three that will examine the importance of stronger intellectual property rights (IPRs) to Canada's economy.
April 12, 2017
MLI argues that Canadian innovation will be harmed if Canada's federal government continues to ignore the intellectual problems the "promise doctrine" creates.
March 1, 2017
This C. D. Howe Institute report assesses the claims that strengthened protection for pharmaceutical patents pursuant to the terms of the the Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union and the TPP would result in an increase in health care costs and provide some estimates of C. D. Howe's own on the issue.
February 1, 2017
Robust intellectual property (IP) protection is vital for biopharmaceutical innovation. It provides the incentives and business certainty needed to attract and sustain long-term investment in prevention, treatments and cures. IP rights have little value without enforcement, however.